TNFalpha-Neutralizing Antibodies
AssigneeEpitomics, Inc.
InventorsFERNANDO JOSE REBELO DO COUTO, Kristin Beth Hendricks, Stacey Ellen Wallace
Life of this patent
Estimating the term…
Abstract
The invention provides monoclonal antibodies that neutralize TNFα activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNFα activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.
Claims23
1-16. (canceled)
A method of treating a subject for a TNFα-related condition, comprising:
- administering monoclonal antibody to a mammalian subject having a TNFα-related condition in an amount effective to treat said subject for at least one symptom of said TNF-α-related condition, wherein said monoclonal antibody neutralizes TNFα activity and comprises:
- a) a variable domain comprising:
- i. a heavy chain variable region comprising a CDR1 region identical to amino acid residues 30-34 of SEQ ID NO:
- 31, a CDR2 region identical to amino acid residues 49-64 of SEQ ID NO:
- 31 and a CDR3 region identical to amino acid residues 97-109 of SEQ ID NO:
- 31;
- and
- ii. a light chain variable region comprising a CDR1 region identical to amino acid residues 23-33 of SEQ ID NO:
- 75, a CDR2 region identical to amino acid residues 49-55 of SEQ ID NO:
- 75 and a CDR3 region identical to amino acid residues 88-99 of SEQ ID NO:
- 75;
- or
- b) a variant of said variable domain of part a) that is otherwise identical to said variable domain of part a) except for up to 10 amino acid substitutions in said CDR regions.
Dependencies are inferred from the claim text.